Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
March 26 (Reuters) - Viking Therapeutics Inc VKTX.O:
VIKING THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT IN PHASE 2 VENTURE-ORAL DOSING TRIAL OF VK2735 TABLET FORMULATION IN PATIENTS WITH OBESITY
VIKING THERAPEUTICS INC: EXPECTS TO REPORT DATA FROM STUDY IN SECOND HALF OF 2025.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Musk’s XChat Is Coming to App Store, Meta, Apple and Finance World Are Trembling

Anthropic IPO 2026: What the Claude Mythos Release Delay Means for Investors and Stock Valuation

Microsoft Launches Its Own AI Models and Ditches OpenAI Dependence - Is MSFT Stock a Buy at $370?

Anthropic Claude Mythos Preview Sparks Wall Street Panic: Bessent, Powell Summon CEOs; Cloudflare Tumbles 8%

Intel Stock's Rare Surge: What’s Driving the Rally and Is It Worth Buying in 2026?

Tradingkey







